Cannabis Canada Comments On C-45
OTTAWA, June 8, 2018 /CNW/ - The Cannabis Council of Canada ("C3 or Cannabis Canada") commends the Senate for approving bill C-45, the Cannabis Act for third reading and returning the bill to the House of Commons.
While C3 is grateful for the dedicated hard work of the Senate, we are concerned that some of the substantive amendments advanced in the final stages of the Act's progression through the upper chamber will serve to work against our common goals of keeping cannabis away from kids and profits away from organised crime.
"Canada's emerging legal cannabis industry is competing against a well funded and sophisticated illegal market," Said Allan Rewak, Executive Director. "Some of the amendments offered in the final stages of debate will place the pioneers of our legal sector at a significant disadvantage in displacing illegal operators," added Rewak.
Moving forward C3 encourages the government of Canada to reject the non-technical amendments to the act that carry unintended consequences, while also ensuring that the commitment made to Canadians, that adult use cannabis will be regulated and legalised in the summer of 2018, is fulfilled.
About the Cannabis Council of Canada:
C3 is the leading organization of Canada's Licensed Producers of Medical Cannabis under Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR).
The Council's mission is to act as the national voice for our members in their promotion of industry standards; support the development, growth and integrity of the regulated cannabis industry; and serve as an important resource on issues related to the safe and responsible use of cannabis for medical and non-medical purposes.
Members of Cannabis Canada share a philosophy of both patient-centric care and improved public health, and are committed to product safety and quality, secure and reliable access and the promotion of the safe and healthful use of cannabis.
SOURCE Cannabis Canada Association
Allan Rewak, Executive Director, [email protected], (647) 206-1231
Share this article